Zoe D. Draelos

Oct 3, 2024 | physiciansweekly.com | Zoe D. Draelos

Dermatologists recently have developed and validated several tools for assessing itch in plaque psoriasis, such as the Peak Pruritus-Numerical Rating Scale. Historically, psoriasis has been considered a non-pruritic skin condition, which has contributed to a lack of standardized methods to evaluate itch in this disease state.

Aug 19, 2024 | onlinelibrary.wiley.com | Zoe D. Draelos |Andrew G. Bushmakin |Pranab Ghosh |Jason J. Xenakis

Supporting Information Filename Description ijd17428-sup-0001-Supinfo.docxWord 2007 document , 25.4 KB Data S1 Supporting Information. References 1, , , . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133: 377–385. 2, . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370: 263–271. 3, , , , , , et al.

Nov 13, 2023 | jofskin.org | Christopher G. Bunick |Neal Bhatia |James Del Rosso |Zoe D. Draelos

Main Article Content Christopher Bunick Neal Bhatia James Del Rosso Zoe Draelos Lawrence Eichnfield Leon Kircik Mark Lebwohl Melinda Gooderham Lawrence Green Adelaide Hebert Ronald Vender Matthew Zirwas Eric Simpson Linda Stein Gold Melissa Seal Scott Snyder David Osborne Patrick Burnett Robert Higham David Chu David Berk Keywords roflumilast cream, roflumilast foam, psoriasis, seborrheic dermatitis, atopic dermatitis, local tolerability References 1. Eastman WJ, et al. Cutis 2014;94:46–53....

Jul 16, 2023 | jofskin.org | Andrew Blauvelt |Zoe D. Draelos |Melinda Gooderham |Edward L Lain

This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles.

Jul 16, 2023 | jofskin.org | Zoe D. Draelos |Emil Tanghetti |Linda Gold |Leon Kircik

Main Article Content Keywords Tolerability, Irritation, CIPT, RIPT, Retinoid, BPO, Adapalene, Clindamycin, Antiobiotic, Combination Abstract Introduction: IDP-126 polymeric mesh gel (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) is the first triple-combination, fixed-dose topical acne product in development and it addresses major acne pathophysiological processes. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability in...